Deep Learning for Glioblastoma Subtyping: Leveraging DenseNet-201 in Brain Tumor Radiogenomic Classification

This research investigates the application of DenseNet-201, a deep convolutional neural network architecture, in the RSNA-MICCAI Brain Tumor Radiogenomic Classification aimed at predicting the genetic subtype of glioblastoma using MRI imaging data. This study demonstrates the effectiveness of DenseNet-201 in accurately classifying glioblastoma cases based on MGMT promoter methylation status, a critical biomarker influencing treatment outcomes. Through comprehensive experimental evaluations, including training, validation, and testing phases, DenseNet-201 exhibits robust performance metrics such as high accuracy, precision, recall, F1-score, and AUC-ROC values. These results highlight the model's ability to effectively distinguish between MGMT promoter methylation-positive and negative glioblastoma cases, offering valuable support for clinical decision-making in treatment planning and prognosis assessment. Leveraging deep learning techniques and MRI imaging data, DenseNet-201 holds promise as a powerful tool for enhancing the understanding of glioblastoma genetics and guiding personalized therapeutic interventions, ultimately contributing to improved patient outcomes in brain cancer management.